Fecal microbiota transplantation in patients with acute and chronic graft‐versus‐host disease—spectrum of responses and safety profile. Results from a prospective, multicenter study

Biliński, Jarosław; Lis, Karol; Tomaszewska, Agnieszka; Grzesiowski, Paweł; Dzieciątkowski, Tomasz; Tyszka, Martyna; Karakulska-Prystupiuk, Ewa; Boguradzki, Piotr; Tormanowska, Magdalena; Hałaburda, Kazimierz; Waszczuk‐Gajda, Anna; Wiktor-Jedrzejczak, W; Basak, Grzegorz W.

doi:10.1002/ajh.26077

Cited by 25 publications

(24 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, all patients responded to FMT and not related severe adverse events to this procedure were observed [ 76 ]. Similar results were obtained in other studies confirming that FMT could be a new treatment option for patients with intestine acute GvHD [ 77 , 78 , 79 ]. Additionally, the safety and efficacy of FMT for grade IV steroid refractory gastrointestinal tract GvHD was recently investigated by Zhao and colleagues [ 80 ].…”

Section: Fecal Microbiota Transplantation In Allogeneic Hematopoietic Stem Cell Transplantationsupporting

confidence: 91%

Gut Microbiome Modulation and Faecal Microbiota Transplantation Following Allogenic Hematopoietic Stem Cell Transplantation

Kaźmierczak-Siedlecka

Skonieczna-Żydecka

Biliński

et al. 2021

Cancers

View full text Add to dashboard Cite

Nowadays, allogenic hematopoietic stem cell transplantation (allo-HSCT) is a curative therapy that is mainly recommended for hematologic malignancies. However, complications (such as graft-versus-host disease, mucositis, disease relapse, and infections) associated with the HSCT procedure contribute to the development of gut microbiota imbalance, gut-barrier disruption, and increased intestinal permeability. In the present narrative review, the crosstalk between gut microbiota products and intestinal homeostasis is discussed. Notably, gut-microbiota-related aspects have an impact on patients’ clinical outcomes and overall survival. In accordance with the most recent published data, gut microbiota is crucial for the treatment effectiveness of many diseases, not only gastrointestinal cancers but also hematologic malignancies. Therefore, it is necessary to indicate a therapeutic method allowing to modulate gut microbiota in HSCT recipients. Currently, fecal microbiota transplantation (FMT) is the most innovative method used to alter/restore gut microbiota composition, as well as modulate its activity. Despite the fact that some previous data have shown promising results, the knowledge regarding FMT in HSCT is still strongly limited, except for the treatment of Clostridium difficile infection. Additionally, administration of prebiotics, probiotics, synbiotics, and postbiotics can also modify gut microbiota; however, this strategy should be considered carefully due to the high risk of fungemia/septicemia (especially in case of fungal probiotics).

show abstract

Section: Fecal Microbiota Transplantation In Allogeneic Hematopoietic Stem Cell Transplantationsupporting

confidence: 91%

Gut Microbiome Modulation and Faecal Microbiota Transplantation Following Allogenic Hematopoietic Stem Cell Transplantation

Kaźmierczak-Siedlecka

Skonieczna-Żydecka

Biliński

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Overall, the FMT has shown an excellent safety profile. However, in a most recent study by Bilinski et al, higher rate of SAEs, including septic shock, sepsis, and norovirus-mediated GI tract infection were observed, which may have been due to the poor general performance status of study patients [64]. Moreover, it was observed that a worse general performance status tended to correlate with more frequent complications.…”

Section: Discussionmentioning

confidence: 87%

Tandem fecal microbiota transplantation cycles in an allogeneic hematopoietic stem cell transplant recipient targeting carbapenem-resistant Enterobacteriaceae colonization: a case report and literature review

Su¹,

Luo²,

Yu³

et al. 2021

Eur J Med Res

View full text Add to dashboard Cite

Background Due to limited antibiotic options, carbapenem-resistant Enterobacteriaceae (CRE) infections are associated with high non-relapse mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Also, intestinal CRE colonization is a risk factor for subsequent CRE infection. Several clinical studies have reported successful fecal microbiota transplantation (FMT) for the gut decontamination of a variety of multidrug-resistant bacteria (MDRB), even in immunosuppressed patients. Similarly, other studies have also indicated that multiple FMTs may increase or lead to successful therapeutic outcomes. Case presentation We report CRE colonization in an allo-HSCT patient with recurrent CRE infections, and its successful eradication using tandem FMT cycles at 488 days after allo-HSCT. We also performed a comprehensive microbiota analysis. No acute or delayed adverse events (AEs) were observed. The patient remained clinically stable with CRE-negative stool culture at 26-month follow-up. Our analyses also showed some gut microbiota reconstruction. We also reviewed the current literature on decolonization strategies for CRE. Conclusions CRE colonization led to a high no-relapse mortality after allo-HSCT; however, well-established decolonization strategies are currently lacking. The successful decolonization of this patient suggests that multiple FMT cycles may be potential options for CRE decolonization.

show abstract

“…Other clinical studies also demonstrated that FMT from related or unrelated donors was effective for the treatment of aGVHD, especially steroid-resistant GI aGVHD [111,[113][114][115][116]147]. A newly published study revealed that FMT was effective for the treatment of GVHD patients by promoting gut decolonization from antibiotic-resistant bacteria [118]. Currently, many clinical studies are investigating the effect of FMT on aGVHD (Tables 2 and 3).…”

Section: Fmtmentioning

confidence: 99%

Roles of the intestinal microbiota and microbial metabolites in acute GVHD

Lin

et al. 2021

Exp Hematol Oncol

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the most curative strategies for the treatment of many hematologic malignancies and diseases. However, acute graft-versus-host disease (GVHD) limits the success of allo-HSCT. The prevention and treatment of acute GVHD is the key issue for improving the efficacy of allo-HSCT and has become a research hotspot. The intestine is the primary organ targeted by acute GVHD, and the intestinal microbiota is critical for maintaining the homeostasis of the intestinal microenvironment and the immune response. Many studies have demonstrated the close association between the intestinal microbiota and the pathogenesis of acute GVHD. Furthermore, dysbiosis of the microbiota, which manifests as alterations in the diversity and composition of the intestinal microbiota, and alterations of microbial metabolites are pronounced in acute GVHD and associated with poor patient prognosis. The microbiota interacts with the host directly via microbial surface antigens or microbiota-derived metabolites to regulate intestinal homeostasis and the immune response. Therefore, intervention strategies targeting the intestinal microbiota, including antibiotics, prebiotics, probiotics, postbiotics and fecal microbiota transplantation (FMT), are potential new treatment options for acute GVHD. In this review, we discuss the alterations and roles of the intestinal microbiota and its metabolites in acute GVHD, as well as interventions targeting microbiota for the prevention and treatment of acute GVHD.

show abstract

Fecal microbiota transplantation in patients with acute and chronic graft‐versus‐host disease—spectrum of responses and safety profile. Results from a prospective, multicenter study

Cited by 25 publications

References 5 publications

Gut Microbiome Modulation and Faecal Microbiota Transplantation Following Allogenic Hematopoietic Stem Cell Transplantation

Gut Microbiome Modulation and Faecal Microbiota Transplantation Following Allogenic Hematopoietic Stem Cell Transplantation

Tandem fecal microbiota transplantation cycles in an allogeneic hematopoietic stem cell transplant recipient targeting carbapenem-resistant Enterobacteriaceae colonization: a case report and literature review

Roles of the intestinal microbiota and microbial metabolites in acute GVHD

Contact Info

Product

Resources

About